Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine
Novartis and Amgen are trying to build a compelling case for the value of their CGRP antagonist erenumab. Novartis said one strategy under consideration is to underwrite the cost of the drug for patients who don't respond.
You may also be interested in...
ICER Says Amgen/Novartis Migraine Drug Aimovig Is Cost Effective At $5,000 Net Price
Amgen said when Aimovig was approved that its $6,900 list price was designed to make sure a lot of patients could access the migraine prophylaxis. ICER now says that's a reasonable price, assuming a $5,000 net cost for the CGRP inhibitor, but only for patients who have failed on other treatments.
Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price
Amgen and Novartis won the first US FDA approval for a CGRP inhibitor in the prevention of migraine headaches. The companies aim to quickly capture a big share of what they estimate to be an 8m-patient market in the US with a $6,900 per year price tag.
As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past
Amgen started 2018 off on solid footing with a 2% jump in Q1 revenue to $5.55bn versus consensus estimates of $5.4bn, but new drugs like the CGRP inhibitor Aimovig are needed to keep the momentum going and supplement declining sales for key products.